
GlaxoSmithKline’s HZ/su vaccine candidate for the prevention of shingles has demonstrated promising benefits across all age groups in a late-stage …

GlaxoSmithKline will be celebrating following the successful Phase III study of its shingles vaccine HZ/su that has met its primary …

